VistaGen Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- VistaGen Therapeutics's estimated annual revenue is currently $892.7M per year.
- VistaGen Therapeutics's estimated revenue per employee is $20,289,091
- VistaGen Therapeutics's total funding is $54.8M.
- VistaGen Therapeutics's current valuation is $341.7M. (January 2022)
Employee Data
- VistaGen Therapeutics has 44 Employees.
- VistaGen Therapeutics grew their employee count by 0% last year.
VistaGen Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP Translational Medicine | Reveal Email/Phone |
2 | VP - Corporate Strategy and Capital Markets | Reveal Email/Phone |
3 | SVP Development Operations | Reveal Email/Phone |
4 | President and Chief Scientific Officer | Reveal Email/Phone |
5 | Chief Financial Officer | Reveal Email/Phone |
6 | Director, CMC Project Management | Reveal Email/Phone |
7 | Chief Legal Officer | Reveal Email/Phone |
8 | CEO and Director | Reveal Email/Phone |
9 | Director Digital Media and Communications Strategy | Reveal Email/Phone |
10 | Senior Director, Legal Operations and Assistant Corporate Secretary | Reveal Email/Phone |
VistaGen Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $84.8M | 422 | 24% | N/A | N/A |
#2 | $0.4M | 2 | 0% | N/A | N/A |
#3 | $32M | 159 | 3% | N/A | N/A |
#4 | $35M | 121 | 3% | $62.5M | N/A |
#5 | $30.2M | 150 | 18% | N/A | N/A |
#6 | $135.3M | 673 | 0% | N/A | N/A |
#7 | $110.3M | 549 | N/A | N/A | N/A |
#8 | $60.1M | 299 | -4% | N/A | N/A |
#9 | $554.8M | 1725 | 2% | N/A | N/A |
#10 | $10.5M | 52 | 4% | N/A | N/A |
What Is VistaGen Therapeutics?
VistaGen Therapeutics (http://www.vistagen-inc.com), a private biotechnology company located in Burlingame, California, USA, is one of the global leaders in the in vitro applications of stem cell technologies for drug discovery and development. VistaGen's portfolio of proprietary stem cell technologies and information products are being introduced to the pharmaceutical industry to accelerate drug development in ways never before possible. VistaGen's internal drug discovery and development programs focusing on cancer, central nervous system (CNS) disorders, and cardiovascular disease will also benefit from the development of these screening systems.
keywords:N/A
$54.8M
Total Funding
44
Number of Employees
$892.7M
Revenue (est)
0%
Employee Growth %
$341.7M
Valuation
N/A
Accelerator
VistaGen Therapeutics News
With an experienced leadership team and a steady flow of near- and long-term potential milestones, VistaGen is passionate about transforming...
VistaGen Therapeutics, Inc. ... VistaGen is currently evaluating PH94B in multiple Phase 3 trials for the acute treatment of anxiety in adults...
Wall Street is positive on Vistagen Therapeutics Inc (VTGN). On average, analysts give the stock a Strong Buy rating.
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders ...
South San Francisco-based biotech firm VistaGen Therapeutics raised $1 million in grant funding from the California Institute for Regenerative Medicine (CIRM) to distribute to researchers and other companies working on stem-cell projects linked to diabetes and neurological disorders, reports Ven ...
Other Companies in South San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $9.5M | 44 | -2% | N/A |
#2 | $33.6M | 45 | -10% | $98M |
#3 | $7.1M | 46 | -32% | N/A |
#4 | $7.1M | 46 | 2% | N/A |
#5 | $3.6M | 46 | 35% | $120M |